ImpediMed

ImpediMed EPS

The Earnings per Share (EPS) of ImpediMed (IPD.AX) as of Nov 16, 2026 is -0.01 AUD. In the previous year, Earnings per Share (EPS) was -0.01 AUD — a change of -2.73% (higher).

EPS

-0.01AUD

YoY

-2.73%

Last updated:

Earnings per Share (EPS) of ImpediMed is 2026 -0.01 AUD. Earnings per Share (EPS) of ImpediMed was 2025 -0.01 AUD. It decreases by -2.73% higher compared to the previous year.

The ImpediMed EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2022
-0.01 AUD
Jan 1, 2023
-0.01 AUD
Jan 1, 2024
-0.01 AUD
Jan 1, 2025
-0.01 AUD
Jan 1, 2026
-0.01 AUD
Jan 1, 2027 (e)
-0.00 AUD
Jan 1, 2028 (e)
-0.00 AUD
Jan 1, 2029 (e)
-0.00 AUD
The ImpediMed EPS history
YEAREPSYoY
est-0.00AUD-39.37%
est-0.00AUD-38.71%
est-0.00AUD-72.10%
-0.01AUD-2.73%
-0.01AUD+28.68%
-0.01AUD+5.10%
-0.01AUD-24.28%
-0.01AUD-14.73%
-0.01AUD-35.55%
-0.02AUD-58.40%
-0.05AUD-32.12%
-0.07AUD-2.05%
-0.07AUD+5.75%
-0.07AUD+37.63%
-0.05AUD+55.17%
-0.03AUD-31.15%
-0.05AUD-34.15%
-0.07AUD-16.54%
-0.09AUD+18.79%
-0.07AUD-36.83%
-0.11AUD+13.17%
-0.10AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

Earnings per Share (EPS) of ImpediMed is -0.01 AUD in 2026.

Earnings per Share (EPS) of ImpediMed changed from -0.01 AUD to -0.01 AUD, representing a -2.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) ImpediMed since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — ImpediMed

All Key Metrics — ImpediMed